MGMT, O-6-methylguanine-DNA methyltransferase, 4255

N. diseases: 444; N. variants: 24
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0025202
Disease: melanoma
melanoma 		0.400 Biomarker disease HPO
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.130 Biomarker group HPO
CUI: C0030297
Disease: Pancreatic Neoplasm
Pancreatic Neoplasm 		0.110 Biomarker disease HPO
CUI: C0016689
Disease: Freckles
Freckles 		0.100 Biomarker phenotype HPO
CUI: C0027960
Disease: Nevus
Nevus 		0.100 Biomarker disease HPO
CUI: C0035309
Disease: Retinal Diseases
Retinal Diseases 		0.100 Biomarker group HPO
CUI: C0038356
Disease: Stomach Neoplasms
Stomach Neoplasms 		0.100 Biomarker group HPO
CUI: C0151908
Disease: Dry skin
Dry skin 		0.100 Biomarker phenotype HPO
CUI: C0234133
Disease: Extrapyramidal sign
Extrapyramidal sign 		0.100 Biomarker phenotype HPO
CUI: C1962966
Disease: Retinopathy, CTCAE
Retinopathy, CTCAE 		0.100 Biomarker phenotype HPO
CUI: C1963094
Disease: Dry Skin, CTCAE
Dry Skin, CTCAE 		0.100 Biomarker phenotype HPO
CUI: C4021976
Disease: Abnormality of the lymphatic system
Abnormality of the lymphatic system 		0.100 Biomarker disease HPO
CUI: C0017638
Disease: Glioma
Glioma 		0.400 Biomarker disease BEFREE <i>FoxD2-AS1</i> is a prognostic factor in glioma and promotes temozolomide resistance in a O<sup>6</sup>-methylguanine-DNA methyltransferase-dependent manner. 31680769 2019
CUI: C0017638
Disease: Glioma
Glioma 		0.400 PosttranslationalModification disease BEFREE <i>O</i>(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation is a high predictive factor for therapy results of temozolomide in patients with glioma. 31422371 2020
CUI: C4289690
Disease: Diffuse Glioma
Diffuse Glioma 		0.020 PosttranslationalModification disease BEFREE <sup>18</sup>F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma. 31426864 2019
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 AlteredExpression disease BEFREE () that outline direct transcriptional regulation of DNA repair enzyme O6-methylguanine DNA methyltransferase (MGMT) in glioblastoma CSCs through NFkB activation. 29644711 2018
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.400 AlteredExpression disease BEFREE () that outline direct transcriptional regulation of DNA repair enzyme O6-methylguanine DNA methyltransferase (MGMT) in glioblastoma CSCs through NFkB activation. 29644711 2018
CUI: C0278878
Disease: Adult Glioblastoma
Adult Glioblastoma 		0.100 AlteredExpression disease BEFREE () that outline direct transcriptional regulation of DNA repair enzyme O6-methylguanine DNA methyltransferase (MGMT) in glioblastoma CSCs through NFkB activation. 29644711 2018
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.100 AlteredExpression disease BEFREE () that outline direct transcriptional regulation of DNA repair enzyme O6-methylguanine DNA methyltransferase (MGMT) in glioblastoma CSCs through NFkB activation. 29644711 2018
CUI: C0017638
Disease: Glioma
Glioma 		0.400 PosttranslationalModification disease BEFREE (11)C-methionine PET could be a useful tool to detect MGMT promoter methylation in nonenhancing glioma. 25178915 2014
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms 		0.400 Biomarker group BEFREE (2) Persistence of prenatal MGMT deficiency into postnatal life in a sub-population of individuals may increase brain tumor risk. 17500046 2007
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 Biomarker group BEFREE (c) Does MGMT protect against tobacco-associated cancer? 21708177 2012
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 Biomarker group BEFREE (c) Does MGMT protect against tobacco-associated cancer? 21708177 2012
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.100 PosttranslationalModification disease BEFREE 17beta-Estradiol decreased DNMT1 and HDAC1 protein expressions and their binding activity on MGMT promoter, and this may partially contribute to the gender difference of MGMT hypermethylation in lung cancer. 19596925 2009
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.100 PosttranslationalModification disease BEFREE 17beta-Estradiol decreased DNMT1 and HDAC1 protein expressions and their binding activity on MGMT promoter, and this may partially contribute to the gender difference of MGMT hypermethylation in lung cancer. 19596925 2009